Meta-pharmacokinetic analysis of posaconazole following dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients vs. healthy volunteers: Impact of clinical characteristics and race.
Chinese
Formulation
Haematology patient
Non-linearity
Oral bioavailability
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
02
06
2023
revised:
29
08
2023
accepted:
25
09
2023
medline:
4
12
2023
pubmed:
9
10
2023
entrez:
8
10
2023
Statut:
ppublish
Résumé
To investigate the potential impact of clinical characteristics and the Chinese race on posaconazole pharmacokinetics in patients using an integrated population pharmacokinetic model for posaconazole oral suspension (SUS), delayed-release tablet (DR-tablet), and intravenous (IV) infusion that was developed in healthy volunteers (HV). 1046 concentrations from 105 prospectively studied Caucasian patients receiving either of the three posaconazole formulations were pooled with 3898 concentrations from 182 HV. Clinical characteristics were tested for significance. The impact of Chinese race was assessed using 292 opportunistic samples from 80 Chinese patients receiving SUS. Bioavailability of SUS (F Pharmacokinetics of posaconazole in patients differ considerably to those in HV, with altered F
Identifiants
pubmed: 37806462
pii: S0924-8579(23)00269-8
doi: 10.1016/j.ijantimicag.2023.106995
pii:
doi:
Substances chimiques
posaconazole
6TK1G07BHZ
Antifungal Agents
0
Tablets
0
Triazoles
0
Suspensions
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106995Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.